<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
Amendment No.: *
Name of Issuer: Allergan Specialty Therapeutics, Inc.
Title of Class of Securities: Class A Common Stock
CUSIP Number: 018494104
(Date of Event Which Requires Filing of this Statement)
April 19, 2000
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
/ / Rule 13d-1(b)
/X/ Rule 13d-1(c)
/ / Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect
to the subject class of securities, and for any subsequent
amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page
shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act
(however, see the Notes).
<PAGE>
CUSIP Number: 018494104
1. Name of Reporting Person
I.R.S. Identification No. of Above Person
Lourde John Constable, d/b/a Constable Asset
Management
2. Check the Appropriate Box if a Member of a Group
a.
b. X
3. SEC Use Only
4. Citizenship or Place of Organization
United States
Number of Shares Beneficially Owned by Each Reporting Person
With:
5. Sole Voting Power:
0
6. Shared Voting Power:
439,000
7. Sole Dispositive Power:
0
8. Shared Dispositive Power:
439,000
9. Aggregate Amount Beneficially Owned by Each Reporting
Person
439,000
10. Check Box if the Aggregate Amount in Row (9) Excludes
Certain Shares
-2-
<PAGE>
11. Percent of Class Represented by Amount in Row (9)
13.41%
12. Type of Reporting Person
IN
-3-
<PAGE>
CUSIP Number: 018494104
1. Name of Reporting Person
I.R.S. Identification No. of Above Person
Constable Partners, L.P.
2. Check the Appropriate Box if a Member of a Group
a.
b. X
3. SEC Use Only
4. Citizenship or Place of Organization
Delaware
Number of Shares Beneficially Owned by Each Reporting Person
With:
5. Sole Voting Power:
0
6. Shared Voting Power:
393,100
7. Sole Dispositive Power:
0
8. Shared Dispositive Power:
393,100
9. Aggregate Amount Beneficially Owned by Each Reporting
Person
393,100
10. Check Box if the Aggregate Amount in Row (9) Excludes
Certain Shares
-4-
<PAGE>
11. Percent of Class Represented by Amount in Row (9)
12.01%
12. Type of Reporting Person
PN
-5-
<PAGE>
This Schedule 13G is being filed to report that the
ownership of Lourde John Constable and Constable Partners,
L.P. (together, the Reporting Persons") in the Class A
Callable Common Stock, $.01 par value per share (the
"Shares") of Allergan Specialty Therapeutics, Inc. (the
"Issuer") is being switched from Schedule 13D to Schedule
13G. The reason for this change is that the Reporting
Persons filed a Schedule 13D and a Schedule 13 Amendment No.
1 on April 27, 1998, and October 16, 1998 respectively,
prior to the enactment of the legislation authorizing filing
for passive investors on Schedule 13G. The changes in the
Reporting Persons' position in the Issuer's Shares during
February, 2000 has prompted a filing and presented the first
appropriate opportunity to switch schedules. This Schedule
13G is also being filed to report that amount of ownership
of the Reporting Persons has changed from 14.5% and 9.97%
respectively, to 13.41% and 12.01%, respectively of the
Shares outstanding.
Item 1(a) Name of Issuer: Allergan Specialty Therapeutics,
Inc.
(b) Address of Issuer's Principal Executive Offices:
2525 Dupont Drive
Irvine, CA 92612
Item 2(a) - (c). Name, Principal Business Address, and
Citizenship of Persons Filing:
Lourde John Constable, d/b/a Constable Asset
Management
Constable Partners, L.P.
5 Radnor Corp. Center
100 Matsonford Rd.
Suite #520
Radnor, Pennsylvania 19087
Mr. Constable - United States citizen
Constable Partners, L.P. - Delaware limited
partnership
(d) Title of Class of Securities: Class A Common
Stock
(e) CUSIP Number: 018494104
-6-
<PAGE>
Item 3. If this statement is filed pursuant to Rule
13d-1(b)(1) or 13d-2(b) or (c) check whether the person
filing is:
(a) / / Broker or dealer registered under Section 15 of
the Act,
(b) / / Bank as defined in Section 3(a)(6) of the Act,
(c) / / Insurance Company as defined in
Section 3(a)(19) of the Act,
(d) / / Investment Company registered under Section 8
of the Investment Company Act,
(e) / / Investment Adviser registered under Section 203
of the Investment Advisers Act of 1940,
(f) / / Employee Benefit Plan, Pension Fund which is
subject to the provisions of the Employee
Retirement Income Security Act of 1974 or
Endowment Fund,
(g) / / Parent Holding Company, in accordance with Rule
13d-1(b)(ii)(G),
(h) / / Savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act,
(i) / / Church plan excluded from the definition of an
investment company under Section 3(c)(14) of
the Investment Company Act,
(j) / / Group, in accordance with Rule 13d-
1(b)(1)(ii)(H).
If this statement is filed pursuant to Rule 13d-1(c), check
this box. /X/
Item 4. Ownership.
(a) Amount Beneficially Owned: John Constable -
439,000; Constable Partners, L.P. - 393,100
(b) Percent of Class: John Constable - 13.41%;
Constable Partners, L.P. - 12.01%
-7-
<PAGE>
(c) John Constable - 439,000 shares with shared
power to vote or to direct the vote; 0 shares
with sole power to vote or to direct the vote;
439,000 shares with shared power to dispose or
to direct the disposition of; 0 shares with the
sole power to dispose or to direct the
disposition of
Constable Partners, L.P. - 393,100 shares with
shared power to vote or to direct the vote; 0
shares with sole power to vote or to direct the
vote; 393,100 shares with shared power to
dispose or to direct the disposition of; 0
shares with the sole power to dispose or to
direct the disposition of
-8-
<PAGE>
Item 5. Ownership of Five Percent or Less of a Class.
N/A
Item 6. Ownership of More than Five Percent on Behalf of
Another Person.
N/A
Item 7. Identification and Classification of the Subsidiary
Which Acquired the Security Being Reported by the
Parent Holding Company.
N/A
Item 8. Identification and Classification of Members of the
Group.
N/A
Item 9. Notice of Dissolution of the Group.
N/A
-9-
<PAGE>
Item 10.
Certification for Rule 13d-1(c): By signing below I
certify that, to the best of my knowledge and belief, the
securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or
influencing the control of the issuer of the securities and
were not acquired and are not held in connection with or as
a participant in any transaction having that purpose or
effect.
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the
information set forth in this statement is true,
complete and correct.
CONSTABLE PARTNERS, L.P.
By: /s/ Lourde John Constable
_____________________________
Lourde John Constable
General Partner
/s/ Lourde John Constable
_____________________________
Lourde John Constable
May 1, 2000
10
02414001.AC9
<PAGE>
Exhibit A
AGREEMENT
The undersigned agree that this Schedule 13G dated
May 1, 2000 relating to the Class A Common Stock of Allergan
Specialties Therapeutics, Inc. shall be filed on behalf of
the undersigned.
CONSTABLE PARTNERS, L.P.
By: /s/ Lourde John Constable
_____________________________
Lourde John Constable
General Partner
/s/ Lourde John Constable
_____________________________
Lourde John Constable
02414001.AC9